Clinical Trial Update: Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B [Phase 2]

View source ↗

Summary

Phase 2 trial comparing AlphaNine with BeneFIX in patients with severe hereditary Hemophilia B to assess efficacy and safety; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• AlphaNine (recombinant coagulation factor IX)
• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Grifols Biologicals, LLC | Conditions: Hemophilia B | Phase 2 | Status: COMPLETED | Results posted: 2017-07-25